Abstract 6754: A payload screening and ADC evaluation platform for STING agonist antibody drug conjugates

Abstract Antibody drug conjugates (ADCs) are a class of rapidly developing targeted biotherapeutic drugs, which consist of three elements: antibody, linker, and payload. ADCs combine the high specificity of antibodies with the potency of payloads, delivering the highly efficient small molecule within the target tumor cells. As one of the new payload types, stimulator of interferon genes (STING) agonist can initiate the innate immune response, enhancing the attack on tumor cells. STING agonist ADCs, allowing tumor-localized activation of STING, may achieve greater anti-tumor activity and better tolerability. By combining the STING binding assay, different THP-1 reporter assay, we can support for STING agonist activities screening. RT-qPCR assay and WB assay can be applied for demonstrating the molecular mechanisms of candidates. For specific screening and evaluation of HER2 STING agonist ADCs, HER2 overexpression reporter assay, co-culture assays of tumor cell lines or STING knockout tumor cell lines with THP-1, hPBMC, as well as whole blood can be utilized at different project stages. Citation Format: Ying Meng, Li Li, Min Kang, Xiao Li, Haiting Dai, Tj (Tiejun) Bing. A payload screening and ADC evaluation platform for STING agonist antibody drug conjugates [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 6754.